Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), child
Stage/Subtype:  untreated childhood acute myeloid leukemia and other myeloid malignancies
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, 2498, NCT01640301
AC220 With 5-Aza or Low Dose Cytarabine
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50CA100632, NCT01892371
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, NCT02053545
Laboratory-Treated (Central Memory/Naïve) CD8+ T Cells in Treating Patients with Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: 9296, NCI-2016-00042, NCT02770820
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Prevention, Treatment
Age: Any age
Trial IDs: MCC-18766, NCI-2017-00072, NCT03018223
Donor Stem Cell Transplant in Treating Patients with High Risk Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 9L-11-8, NCI-2013-00447, HS-12-00080, NCT01801046
Selinexor with Combination Chemotherapy in Treating Patients with Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB15-0412, NCI-2015-01647, NCT02573363
Individualized High Dose Methotrexate in Treating Younger Patients With Cancer and Significant Risk for Side Effects
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 22
Trial IDs: H-33119, NCI-2014-00923, NCT02076997
Start Over